← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Pacific Biosciences PACB $609M	155	+37	+31%	$809M
27	27 Vericel Corp VCEL $2.1B	150	+18	+14%	$635M
28	28 CareDx CDNA $3.45B	148	+9	+6%	$914M
29	NVTA 29 DELISTED Invitae Corporation NVTA	142	+2	+1%	$636M
30	30 Intellia Therapeutics NTLA $1.59B	141	-16	-10%	$430M
31	31 Veracyte VCYT $3.57B	125	+14	+13%	$465M
32	32 Fate Therapeutics FATE $231M	122	+6	+5%	$762M
33	33 Atara Biotherapeutics ATRA $96.9M	121	+6	+5%	$1.68B
34	34 Voyager Therapeutics VYGR $127M	116	-3	-3%	$262M
35	ATHX 35 DELISTED Athersys, Inc. Common Stock ATHX	106	+7	+7%	$41.8M
36	36 Lineage Cell Therapeutics LCTX $250M	105	-1	-0.9%	$52.1M
37	37 Abeona Therapeutics ABEO $266M	99	-5	-5%	$232M
38	38 Standard BioTools LAB $258M	99	+20	+25%	$426M
39	NSTG 39 DELISTED NanoString Technologies, Inc. NSTG	95	+8	+9%	$405M
40	40 uniQure QURE $1.56B	94	-5	-5%	$656M
41	BLCM 41 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	92	-8	-8%	$68.7M
42	42 Wave Life Sciences WVE $629M	92	0	0%	$1.03B
43	43 Guardant Health GH $22.3B	88	+88	–	$2.32B
44	44 Rocket Pharmaceuticals RCKT $259M	87	+3	+4%	$622M
45	45 DELISTED Adverum Biotechnologies ADVM	86	-15	-15%	$121M
46	46 Lakefront Biotherapeutics American Depositary Shares LKFT $1.96B	85	-7	-8%	$746M
47	ADAP 47 DELISTED Adaptimmune Therapeutics ADAP	80	-13	-14%	$397M
48	48 Allogene Therapeutics ALLO $463M	79	+79	–	$1.68B
49	PTE 49 DELISTED PolarityTE, Inc. Common Stock PTE	78	+9	+13%	$160M
50	50 Solid Biosciences SLDB $615M	75	-1	-1%	$648M